NCT01303692已完成不适用
Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 312
- 试验地点
- 1
- 主要终点
- comparison of bone density between GnRH agonist alone vs. CAB group
研究概览
简要总结
Comparison of bone mineral loss in prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent
详细描述
MC MD
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Korean prostate cancer over 50 years old with pathological confirmation
- •Patients receiving GnRH antagonist or GnRH agonist plus anti- androgen combination within 6 months since starting.
- •Patients measured bone density level before starting to receive hormone therapies above.
排除标准
- •Patients who are treated other anti-osteoporosis drugs and who are treated bisphosphate due to BMD T score below -3.
- •Patients who are hard to be analysed by attach to other bone disease.
- •Patients who are hard to be analysed by limitation of chart record according to investigators'discretion.
结局指标
主要结局
comparison of bone density between GnRH agonist alone vs. CAB group
时间窗: 1 year
comparison of bone density before and after hormone therapy
时间窗: 1 year
次要结局
- correlation between osteoporosis risk factors such as age, weight, history of smoke, history of alcohol and bone density value(1 year)
- correlation between osteoporosis risk factors such as age, weight, history of smoke, history of alcohol and bone density value before and after hormone therapy(1 year)
- 1year comparison of FRAX score before and after hormonal therapy(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Bone Health Observational StudyProstate CancerNCT00632905CMX Research599
已完成
3 期
Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate CancerProstate CancerNCT00426777CMX Research160
已完成
不适用
Effect of Androgen Suppression on Bone Loss in Patients With or Without Bone Metastases Secondary to Prostate CancerProstate CancerOsteoporosisNCT00003903University of Rochester150
已完成
2 期
Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer PatientsBone MetastasesProstate CancerNCT03336983Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia126
招募中
不适用
BONE MINERAL DENSITY IN PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPYosteoporosisbone loss1001329610038364NL-OMON37103Sint Franciscus Gasthuis51